Aldatu Biosciences has established the Pan Degenerate Amplification and Adaptation (PANDAA™) platform to enable target detection in highly variable genomic regions with RT-PCR. Our proprietary PANDAA technology allows the development of fast, reliable, and cost-effective diagnostic tests for infectious diseases. Our pipeline includes products for the detection of SARS-CoV-2, Lassa virus, and drug-resistant HIV variants. The high-throughput, low-cost PANDAA platform improves patient healthcare access and outcomes.
WATERTOWN, Mass., February 24, 2021 (PR Web) – Aldatu Biosciences, the leader in adaptive PCR diagnostics, announced the opening of…
Despite national supply constraints, one of the major Boston hospitals now has the ability to do rapid in-house testing and they are conducting the highest volume of on-site hospital testing in New England, thanks to Boston-based startup, Aldatu Biosciences.
ALDATU BIOSCIENCES 2021.